Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

The intervention being tested is Dupilumab, a drug administered via subcutaneous injection. It is intended to manage symptoms of PN, particularly the intense itching associated with the condition.

One abstract reviewed results from Part A and Part C. 1 Part A was a 24-week study comparing dupilumab 300 mg vs placebo and Part C was a 28-week extended active treatment period for patients who ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

Dupilumab is an effective and safe treatment option for patients with atopic dermatitis (AD) in real-life settings, including those with malignancy and other medical comorbidities, according to a ...

Meeting Coverage > CHEST Biologic Dupilumab Shows Sustained Benefit in Asthma Patients — Reduced oral corticosteroid use, improved lung function maintained after nearly 2 years by Salynn Boyles ...

Meeting Coverage > ACG Dupilumab Helped Kids With Eosinophilic Esophagitis Achieve Needed Weight Gain — The drug also met primary endpoint of reducing peak esophageal intraepithelial eosinophil ...

BOSTON — Dupilumab reduced exacerbations and improved lung function in children with asthma, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual ...

Boguniewicz, M., et al. (2024). Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities. Advances in Therapy. doi.org/10.1007/s12325-024-02998-4.

Dupilumab (Dupixent) relieves signs and symptoms of eosinophilic esophagitis (EoE) for up to 52 weeks, researchers say. Few side effects, other than injection pain, emerged in the year-long phase ...

Dupilumab was also associated with improvements in lung function (change in pre-bronchodilator FEV 1 from baseline to week 12: 160mL vs 77mL for placebo; P <.0001) that were sustained through 52 ...